Category: Latest News

180 Life Sciences Corp (NASDAQ:ATNF) stock fell 25% following the company’s announcement of a sales agreement that could see up to $500 million in common stock sold. The biopharmaceutical firm disclosed on August 13, 2025, that it had established an “at-the-market” offering program with Clear Street LLC serving as the sales agent. Under this arrangement,…

Aquestive Therapeutics Inc (NASDAQ:AQST) stock climbed 5.7% following the announcement of a $75 million strategic funding agreement with RTW Investments, LP, contingent on FDA approval of its Anaphylm sublingual film. The financing is intended to support Aquestive through 2027, providing capital to commercialize Anaphylm, which could become the first oral rescue treatment for severe allergic…

Aebi Schmidt Holding AG (NASDAQ:AEBI) stock fell 15.4% after the specialty vehicle manufacturer reported a second-quarter net loss following its recent merger with The Shyft Group. The company, which completed the merger on July 1, posted second-quarter sales of $277.7 million, up 4.2% from $266.5 million in the same period last year. Despite higher sales,…

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock fell 6% following Sarepta Therapeutics’ (NASDAQ:SRPT) sale of over 9.2 million Arrowhead shares in a privately negotiated block trade. Sarepta expects to receive at least $174 million in gross proceeds from the transaction. In addition, approximately 2.66 million Arrowhead shares will be transferred to satisfy $50 million of a previously…

Tilray Brands Inc (NASDAQ:TLRY) stock fell 12.8% following the company’s announcement that it has requested an extension to regain compliance with Nasdaq’s minimum share price rules. The cannabis and consumer goods company is considering several options, including a potential stockholder-approved reverse stock split, to maintain its Nasdaq listing. Tilray’s shares have been trading below the…

Schrödinger Inc (NASDAQ:SDGR) shares dropped 13.7% following the company’s announcement that it is discontinuing development of its CDC7 inhibitor, SGR-2921, which was being evaluated in a Phase 1 study for leukemia patients. The decision comes after two treatment-related deaths occurred in the Phase 1 dose-escalation trial involving patients with relapsed/refractory acute myeloid leukemia (AML) or…

Ulta Beauty (NASDAQ:ULTA) shares dropped 2% Thursday morning following the announcement that the company will not renew its shop-in-shop partnership with Target (NYSE:TGT) when the current agreement expires in August 2026. The partnership, which began in 2021, will continue until its expiration, with Ulta Beauty at Target locations operating in-store and online at Target.com. Customers…

Beam Therapeutics Inc. (NASDAQ:BEAM) shares jumped 12% following the announcement that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, the company’s investigational cell therapy for sickle cell disease. The RMAT designation, which comes after an earlier orphan drug designation, provides Beam with opportunities for closer FDA…

Lazydays Holdings, Inc. (NASDAQ:GORV) posted a second-quarter net loss of $6.67 per share on revenue of $131.3 million Thursday, showing progress in its turnaround efforts despite significantly lower sales volumes. Shares edged up 0.95% in after-hours trading following the results. Revenue declined 44.3% year-over-year from $235.6 million in Q2 2024, reflecting the company’s streamlined footprint…

The Oncology Institute, Inc. (NASDAQ:TOI) saw its shares fall 7.07% in pre-market trading Thursday after reporting second-quarter earnings that fell short of analyst expectations, despite posting revenue above forecasts. The value-based community oncology provider reported a loss of $0.15 per share for Q2, missing estimates of a $0.09 loss by $0.06. Revenue, however, reached $119.8…